Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2023-04-11 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2022年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2022 年年度报告全文" which translates to "2022 Annual Report Full Text" for 葵花药业集团股份有限公司 (Sunflower Pharmaceutical Group Co., Ltd.). It contains detailed sections including company overview, financial data, management discussion and analysis, governance, social responsibility, and full financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management analysis, and detailed business descriptions, consistent with a full annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-11 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2022 Annual Report Summary" of a company, containing detailed financial data for the year 2022, including total assets, net profit, revenue, quarterly financial data, shareholder information, business overview, strategic plans, risk factors, and future outlook. It is comprehensive and covers the company's full-year performance and strategic direction. The length is over 14,000 characters, indicating it is not a brief announcement. The content matches the characteristics of an Annual Report (10-K) rather than a short summary or announcement. Therefore, the document is classified as an Annual Report (10-K). FY 2022
2023-04-11 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2022 by 葵花药业集团股份有限公司. It contains detailed descriptions of the company's internal control environment, risk assessment, control activities, and evaluation conclusions. The content focuses on internal control effectiveness, governance, risk management, and compliance with internal control standards. It does not present full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is not an announcement or a brief summary but a detailed report on internal control self-assessment. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluations. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-11 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized report on non-operating fund occupation and other related party fund transactions for the year 2022 by 葵花药业集团股份有限公司. It includes audited financial data and a summary table of related party transactions, with references to the audit report issued on April 11, 2023. The document is titled as a '专项报告' (special report) and is focused on a specific regulatory requirement related to fund occupation and related party transactions, not a full annual report or interim report. It is a standalone audit-related report addressing compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document length is 2756 characters, which is relatively short but contains substantive financial data and audit confirmation. This fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-11 Chinese
关于2023年度向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for a comprehensive credit facility with banks for the year 2023. It details the credit limit, usage, authorization, and board approval. There is no financial statement, detailed financial data, or report content. The document is a formal announcement about financing activities, specifically about credit facilities and bank loans. This fits the definition of a Capital/Financing Update (CAP). The document length is short and it is not a report publication or certification. Therefore, the classification is CAP with high confidence.
2023-04-11 Chinese
公司2022年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled as 葵花药业集团股份有限公司2022 年度董事会工作报告, which translates to 'Sunflower Pharmaceutical Group Co., Ltd. 2022 Annual Board of Directors Work Report'. It contains detailed sections on the company's 2022 business review, financial performance, governance, board activities, and strategic plans for 2023. The content includes comprehensive financial data, management discussion, governance details, and board meeting summaries. This type of document is a detailed report from the board of directors about the company's operations and governance for the year, which aligns with the category of Management Reports (MDA). It is not an Annual Report (10-K) as it does not present the full financial statements and comprehensive annual disclosures, nor is it a Board/Management Information announcement (MANG) which typically focuses on changes in board or management personnel. The length and detail confirm it is a substantive report rather than a brief announcement or certification. Therefore, the appropriate classification is Management Reports (MDA).
2023-04-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.